Pennsaid Amended NDA Has Mid-December User Fee Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Nuvo’s Class 2 resubmission includes data from a Phase III efficacy trial and single-arm, long-term safety study.
You may also be interested in...
Nuvo's Pennsaid “Approvable” For Osteoarthritis
Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.
Nuvo's Pennsaid “Approvable” For Osteoarthritis
Company plans to meet with FDA in early 2007 to discuss the topical non-steroidal anti-inflammatory treatment.
Paladin Assumes All Canadian Marketing Of Nuvo’s Pennsaid
Montreal company will now receive all revenues from osteoarthritis agent after acquiring rights from Nuvo’s promotional partner Solvay.